Compare Citius Pharmaceuticals Inc (CTXR) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gemini Space Station Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Gemini Space Station Inc trades at $4.02 (market cap $517.11M). The key difference: Gemini Space Station Inc is far larger — about 27.6× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | GEMI | |
|---|---|---|
Market Cap | $18.73M | $517.11M |
Sector | Health | Technology |
52-Week High | $1.82 | $32.52 |
52-Week Low | $0.48 | $3.90 |
Enterprise Value | $14.95M | $507.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
